Zydus receives final approval from the USFDA for Clobazam Tablets

Zydus receives final approval from the USFDA for Clobazam Tablets

Zydus Cadila has received the final approval from the USFDA to market Clobazam Tablets, (US RLD – ONFI® Tablet), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (termed as Lennox-Gastaut syndrome) that also causes developmental and behavioural problems. The group now has 224 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.